Skip to main content
Top
Published in:

Open Access 01-12-2017 | Research

Hemoglobin A1c and risk of left atrial thrombus and spontaneous echo contrast in non-valvular atrial fibrillation patients

Authors: Rong-Ren Kuang, Fang-Zhou Liu, Yun-Peng Li, Wei-Dong Lin, Hua-Sheng Liang, Ai-Hua Chen

Published in: European Journal of Medical Research | Issue 1/2017

Login to get access

Abstract

Objectives

To evaluate the relationship between hemoglobin A1c (HbA1c) and risk of left atrial thrombus/spontaneous echo contrast (LAT/SEC) in non-valvular atrial fibrillation (AF) patients.

Methods

In this retrospective study, 1158 consecutive non-valvular AF patients undergoing transesophageal echocardiography prior to radiofrequency catheter ablation or electric cardioversion were enrolled. Baseline characteristics were collected and analyzed.

Results

There were 87 (7.5%) patients with LAT/SEC. The HbA1c levels in the patients with LAT/SEC were significantly higher than that in patients without LAT/SEC (6.13 ± 0.41 vs. 5.89 ± 0.45 μmol/L, P < 0.001). The optimal cut-off point for HbA1c predicting LAT/SEC was 6.1% determined by receiver-operating characteristic curve. The area under the curve is 0.788 (95% confidence interval: 0.764–0.812). HbA1c ≥6.1% was an independent risk factor for LAT/SEC (odds ratio, 1.74; 95% confidence interval, 1.01–2.98; P = 0.045).

Conclusions

Elevated HbA1c indicated a significantly increased risk for LAT/SEC in non-valvular AF patients. HbA1c might have significance in predicting the risk for prothrombotic state in non-valvular AF patients.
Literature
1.
go back to reference Aliot E, Breithardt G, Brugada J, Camm J, Lip GY, Vardas PE, et al. An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality. Europace. 2010;12:626–33.CrossRefPubMedPubMedCentral Aliot E, Breithardt G, Brugada J, Camm J, Lip GY, Vardas PE, et al. An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality. Europace. 2010;12:626–33.CrossRefPubMedPubMedCentral
2.
go back to reference Miller PS, Andersson FL, Kalra L. Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated? Stroke. 2005;36:360–6.CrossRefPubMed Miller PS, Andersson FL, Kalra L. Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated? Stroke. 2005;36:360–6.CrossRefPubMed
3.
go back to reference Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N–9N.CrossRefPubMed Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N–9N.CrossRefPubMed
4.
go back to reference Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61:755–9.CrossRefPubMed Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61:755–9.CrossRefPubMed
5.
go back to reference Bernhardt P, Schmidt H, Hammerstingl C, Luderitz B, Omran H. Atrial thrombi-a prospective follow-up study over 3 years with transesophageal echocardiography and cranial magnetic resonance imaging. Echocardiography. 2006;23:388–94.CrossRefPubMed Bernhardt P, Schmidt H, Hammerstingl C, Luderitz B, Omran H. Atrial thrombi-a prospective follow-up study over 3 years with transesophageal echocardiography and cranial magnetic resonance imaging. Echocardiography. 2006;23:388–94.CrossRefPubMed
6.
go back to reference Bernhardt P, Schmidt H, Hammerstingl C, Luderitz B, Omran H. Patients with atrial fibrillation and dense spontaneous echo contrast at high risk a prospective and serial follow-up over 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging. J Am Coll Cardiol. 2005;45:1807–12.CrossRefPubMed Bernhardt P, Schmidt H, Hammerstingl C, Luderitz B, Omran H. Patients with atrial fibrillation and dense spontaneous echo contrast at high risk a prospective and serial follow-up over 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging. J Am Coll Cardiol. 2005;45:1807–12.CrossRefPubMed
7.
go back to reference Saliba W, Barnett-Griness O, Elias M, Rennert G. Glycated hemoglobin and risk of first episode stroke in diabetic patients with atrial fibrillation: a cohort study. Heart Rhythm. 2015;12:886–92.CrossRefPubMed Saliba W, Barnett-Griness O, Elias M, Rennert G. Glycated hemoglobin and risk of first episode stroke in diabetic patients with atrial fibrillation: a cohort study. Heart Rhythm. 2015;12:886–92.CrossRefPubMed
8.
go back to reference Lei C, Wu B, Liu M, Chen Y. Association between hemoglobin A(1)C levels and clinical outcome in ischemic stroke patients with or without diabetes. J Clin Neurosci. 2015;22:498–503.CrossRefPubMed Lei C, Wu B, Liu M, Chen Y. Association between hemoglobin A(1)C levels and clinical outcome in ischemic stroke patients with or without diabetes. J Clin Neurosci. 2015;22:498–503.CrossRefPubMed
9.
go back to reference Romero J, Cao JJ, Garcia MJ, Taub CC. Cardiac imaging for assessment of left atrial appendage stasis and thrombosis. Nat Rev Cardiol. 2014;11:470–80.CrossRefPubMed Romero J, Cao JJ, Garcia MJ, Taub CC. Cardiac imaging for assessment of left atrial appendage stasis and thrombosis. Nat Rev Cardiol. 2014;11:470–80.CrossRefPubMed
10.
go back to reference Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.CrossRefPubMed Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.CrossRefPubMed
11.
go back to reference January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JJ, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1–76.CrossRefPubMed January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JJ, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1–76.CrossRefPubMed
12.
go back to reference Kornej J, Apostolakis S, Bollmann A, Lip GY. The emerging role of biomarkers in atrial fibrillation. Can J Cardiol. 2013;29:1181–93.CrossRefPubMed Kornej J, Apostolakis S, Bollmann A, Lip GY. The emerging role of biomarkers in atrial fibrillation. Can J Cardiol. 2013;29:1181–93.CrossRefPubMed
13.
go back to reference Gonzalez-Gonzalez JG, Rodriguez-Gutierrez R, Lavalle-Gonzalez FJ, Gonzalez-Cantu A, Tamez-Perez HE, Gonzalez-Saldivar G, et al. Hemoglobin A1c: a reliable and accurate test for diabetes care? A prospective study in Mexico. Salud Publica Mex. 2013;55:462–8.CrossRefPubMed Gonzalez-Gonzalez JG, Rodriguez-Gutierrez R, Lavalle-Gonzalez FJ, Gonzalez-Cantu A, Tamez-Perez HE, Gonzalez-Saldivar G, et al. Hemoglobin A1c: a reliable and accurate test for diabetes care? A prospective study in Mexico. Salud Publica Mex. 2013;55:462–8.CrossRefPubMed
14.
go back to reference Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the action to control cardiovascular risk in diabetes study). Am J Cardiol. 2014;114:1217–22.CrossRefPubMedPubMedCentral Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the action to control cardiovascular risk in diabetes study). Am J Cardiol. 2014;114:1217–22.CrossRefPubMedPubMedCentral
15.
go back to reference Sandhu RK, Conen D, Tedrow UB, Fitzgerald KC, Pradhan AD, Ridker PM, et al. Predisposing factors associated with development of persistent compared with paroxysmal atrial fibrillation. J Am Heart Assoc. 2014;3:e916.CrossRef Sandhu RK, Conen D, Tedrow UB, Fitzgerald KC, Pradhan AD, Ridker PM, et al. Predisposing factors associated with development of persistent compared with paroxysmal atrial fibrillation. J Am Heart Assoc. 2014;3:e916.CrossRef
16.
go back to reference Iguchi Y, Kimura K, Shibazaki K, Aoki J, Sakai K, Sakamoto Y, et al. HbA1c and atrial fibrillation: a cross-sectional study in Japan. Int J Cardiol. 2012;156:156–9.CrossRefPubMed Iguchi Y, Kimura K, Shibazaki K, Aoki J, Sakai K, Sakamoto Y, et al. HbA1c and atrial fibrillation: a cross-sectional study in Japan. Int J Cardiol. 2012;156:156–9.CrossRefPubMed
17.
go back to reference Goudis CA, Korantzopoulos P, Ntalas IV, Kallergis EM, Liu T, Ketikoglou DG. Diabetes mellitus and atrial fibrillation: pathophysiological mechanisms and potential upstream therapies. Int J Cardiol. 2015;184:617–22.CrossRefPubMed Goudis CA, Korantzopoulos P, Ntalas IV, Kallergis EM, Liu T, Ketikoglou DG. Diabetes mellitus and atrial fibrillation: pathophysiological mechanisms and potential upstream therapies. Int J Cardiol. 2015;184:617–22.CrossRefPubMed
18.
go back to reference Ikeda F, Doi Y, Ninomiya T, Hirakawa Y, Mukai N, Hata J, et al. Haemoglobin A1c even within non-diabetic level is a predictor of cardiovascular disease in a general Japanese population: the Hisayama Study. Cardiovasc Diabetol. 2013;12:164.CrossRefPubMedPubMedCentral Ikeda F, Doi Y, Ninomiya T, Hirakawa Y, Mukai N, Hata J, et al. Haemoglobin A1c even within non-diabetic level is a predictor of cardiovascular disease in a general Japanese population: the Hisayama Study. Cardiovasc Diabetol. 2013;12:164.CrossRefPubMedPubMedCentral
19.
go back to reference Oh HG, Rhee EJ, Kim TW, Lee KB, Park JH, Yang KI, et al. Higher glycated hemoglobin level is associated with increased risk for ischemic stroke in non-diabetic korean male adults. Diabetes Metab J. 2011;35:551–7.CrossRefPubMedPubMedCentral Oh HG, Rhee EJ, Kim TW, Lee KB, Park JH, Yang KI, et al. Higher glycated hemoglobin level is associated with increased risk for ischemic stroke in non-diabetic korean male adults. Diabetes Metab J. 2011;35:551–7.CrossRefPubMedPubMedCentral
20.
go back to reference Lemkes BA, Hermanides J, Devries JH, Holleman F, Meijers JC, Hoekstra JB. Hyperglycemia: a prothrombotic factor? J Thromb Haemost. 2010;8:1663–9.CrossRefPubMed Lemkes BA, Hermanides J, Devries JH, Holleman F, Meijers JC, Hoekstra JB. Hyperglycemia: a prothrombotic factor? J Thromb Haemost. 2010;8:1663–9.CrossRefPubMed
21.
go back to reference Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, et al. Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science. 1992;258:651–3.CrossRefPubMed Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, et al. Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science. 1992;258:651–3.CrossRefPubMed
22.
go back to reference Yamagishi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol. 2011;46:217–24.CrossRefPubMed Yamagishi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol. 2011;46:217–24.CrossRefPubMed
Metadata
Title
Hemoglobin A1c and risk of left atrial thrombus and spontaneous echo contrast in non-valvular atrial fibrillation patients
Authors
Rong-Ren Kuang
Fang-Zhou Liu
Yun-Peng Li
Wei-Dong Lin
Hua-Sheng Liang
Ai-Hua Chen
Publication date
01-12-2017
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2017
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-017-0257-x